Quantcast

Industry news that matters to you.  Learn more

Omicia and LabCorp Collaborate to Offer Comprehensive Genomic Analysis Services for Next-Generation Clinical Trials

Omicia, Inc. recently announced that Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by Laboratory Corporation of America® Holdings (LabCorp®) for its clinical trials sequencing services. LabCorp’s broad menu of testing services, combined with Omicia’s flexible, powerful, and easy-to-use genome analysis platform, will allow the companies to provide a comprehensive suite of expert tools and services for incorporating genomic data into clinical trials. Omicia’s software allows users to quickly and easily annotate genomes, analyze variant data, and generate customized clinical reports for individual patients and research projects across a broad range of disease states and clinical trial designs. Customers can also store, analyze, and manage their clinical trial data within a highly secure environment.

LabCorp Clinical Trials Selected as a Preferred Provider for Global Central Laboratory Services by Bristol-Myers Squibb

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) recently announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers Squibb Company (NYSE: BMY).

“We are excited to expand our relationship with Bristol-Myers Squibb to provide a more flexible and integrated approach to laboratory testing services in support of their innovative clinical development pipeline”
The five-year agreement builds on a long-standing partnership between the two companies during which LabCorp’s global central lab, biomarker and specialty testing capabilities have supported various Bristol-Myers Squibb early and late-stage clinical development programs.

“We are excited to expand our relationship with Bristol-Myers Squibb to provide a more flexible and integrated approach to laboratory testing services in support of their innovative clinical development pipeline,” said Dr. Mark Brecher, LabCorp’s Chief Medical Officer.

Source: Business Wire

Veridex and LabCorp Agreement Brings CellSearch CTC Test to China

Veridex, LLC recently announced an agreement with LabCorp Clinical Trials that makes the CELLSEARCH® circulating tumor cell (CTC) test available for researchers conducting clinical trials in China. This marks the first clinical reference laboratory in China that offers CTC testing and comes on the heels of China’s State Food & Drug Administration approval of CELLSEARCH® as an in vitro diagnostic to manage patients with metastatic breast cancer.

Verastem Enters Biomarker Agreement with LabCorp for Cancer Stem Cell Agent Companion Diagnostic

Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, entered an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to validate biomarkers for its lead focal adhesion kinase (FAK) inhibitor VS-6063 in the development of an applicable companion diagnostic.

Two Major Reference Labs Sign With Critical Diagnostics

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Quest Diagnostics (NYSE: DGX) and its subsidiary Berkeley HeartLab, announced recently an agreement under which both Quest and Berkeley HeartLab will offer ST2 testing services based on Critical Diagnostics’ Presage ST2 Assay. Critical Diagnostics has also signed an agreement with Laboratory Corporation of America (NYSE: LH), better known as LabCorp, to offer testing of the Presage ST2 Assay. Combined, these two diagnostic market leaders perform some one-and-a-half million tests per day.